Cantor Fitzgerald Reiterates Overweight on Lucid Diagnostics, Maintains $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Ross Osborn has reiterated an Overweight rating on Lucid Diagnostics (NASDAQ:LUCD) and maintained a $4 price target.
September 26, 2023 | 3:45 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Cantor Fitzgerald analyst Ross Osborn has reiterated an Overweight rating on Lucid Diagnostics and maintained a $4 price target.
The news is directly about Lucid Diagnostics and is likely to influence investor sentiment. However, as the rating and price target have been maintained, the immediate impact on the stock price may be neutral.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100